Amgen Hopes Kyprolis Label Expansion Will Give It A Leg Up In The Myeloma Market
This article was originally published in The Pink Sheet Daily
Firm believes addition of data from the ENDEAVOR trial, and new claims, will establish the proteasome inhibitor as a backbone of choice across lines of therapy.
You may also be interested in...
Sponsors of established products like Amgen's Kyprolis and Blincyto and Bristol's Sprycel work to bulk up labeling with new indications while FDA reviews at least six novel agents for blood cancers.
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.
Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.